Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
54.69 USD
↗ 0.41 (0.76%)AT CLOSE (11:59 AM EDT)
54.45
↘ 0.24 (0.44%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
54.45
↘ 0.24 (0.44%)
🔴Market: CLOSED

Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $54.68. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 25, 2026.

Open?$54.34
High?$55.24
Low?$53.59
Prev. Close?$54.28
Volume?2.5M
Avg. Volume?4.2M
VWAP?$54.71
Rel. Volume?0.59x
Bid / Ask
Bid?$52.65 × 100
Ask?$56.25 × 100
Spread?$3.60
Midpoint?$54.45
Valuation & Ratios
Market Cap?24.2B
Shares Out?443.3M
Float?435.9M
Float %?98.3%
P/E Ratio?29.30
P/B Ratio?3.52
EPS?$1.87
Dividend?3.03%
Ex-Dividend?N/A
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Asset Management & Capital Markets›Private Equity & Alternative InvestmentsBiotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Immunotherapy & Immuno-Oncology
Employees
100
Market Cap
24.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
38
Momentum?
73
Short Sent.?
57
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.08Grey
Confidence?75%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.55%Low
Short Interest?11.1M
Days to Cover?3.0
Free Float435.9M
Avg Daily Volume3.7M
Settlement Date2026-06-15
Financial Health
Current Ratio?2.66Strong
Quick Ratio?2.66Strong
Cash Ratio?1.09Strong
Debt/Equity?1.30Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
47/100
P/E?
Peers
100
S&P
36
29.3FAIR▾
P/B?
Peers
100
S&P
49
3.52FAIR▾
P/S?
Peers
100
S&P
8
9.93HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
19
22.2HIGH▾
EV/Sales?
Peers
100
S&P
6
13.37HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
43
12.0%STRONG▾
ROA?
Peers
50
S&P
38
4.2%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$32.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist